14.30
price up icon4.38%   0.60
after-market Handel nachbörslich: 14.09 -0.21 -1.47%
loading
Schlusskurs vom Vortag:
$13.70
Offen:
$13.71
24-Stunden-Volumen:
753.85K
Relative Volume:
0.81
Marktkapitalisierung:
$1.04B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.67M
KGV:
-5.2381
EPS:
-2.73
Netto-Cashflow:
$-97.30M
1W Leistung:
+0.42%
1M Leistung:
-8.92%
6M Leistung:
+16.73%
1J Leistung:
+18.28%
1-Tages-Spanne:
Value
$13.65
$14.54
1-Wochen-Bereich:
Value
$13.22
$14.54
52-Wochen-Spanne:
Value
$8.241
$18.38

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name
Firmenname
Mineralys Therapeutics Inc
Name
Telefon
(888) 378-6240
Name
Adresse
150 N. RADNOR CHESTER ROAD, RADNOR
Name
Mitarbeiter
51
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
MLYS's Discussions on Twitter

Vergleichen Sie MLYS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MLYS
Mineralys Therapeutics Inc
14.30 1.04B 0 -119.67M -97.30M -2.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-11 Eingeleitet Jefferies Hold
2024-07-10 Eingeleitet H.C. Wainwright Buy
2024-04-02 Eingeleitet Goldman Buy
2023-03-07 Eingeleitet BofA Securities Buy
2023-03-07 Eingeleitet Credit Suisse Outperform
2023-03-07 Eingeleitet Evercore ISI Outperform
2023-03-07 Eingeleitet Guggenheim Buy
2023-03-07 Eingeleitet Stifel Buy
2023-03-07 Eingeleitet Wells Fargo Overweight
Alle ansehen

Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten

pulisher
Jun 18, 2025

Mineralys stock holds Buy rating at H.C. Wainwright after CKD trial - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Mineralys enhances lorundrostat data package ahead of planned NDA - The Pharma Letter

Jun 18, 2025
pulisher
Jun 18, 2025

Mineralys Therapeutics (MLYS): Analyst Reiterates Buy Rating and Price Target | MLYS Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Promising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment Appeal - TipRanks

Jun 18, 2025
pulisher
Jun 17, 2025

Mineralys reports positive phase 2 data for lorundrostat in CKD By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Mineralys reports positive phase 2 data for lorundrostat in CKD - Investing.com Australia

Jun 17, 2025
pulisher
Jun 17, 2025

Mineralys Therapeutics Shares Climb on Strong Results from Kidney Disease Trial - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Positive Phase II Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Promising Phase 2 Trial Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating and $42 Price Target - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Transcript : Mineralys Therapeutics, Inc.Special Call - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Mineralys Therapeutics stock jumps after positive kidney disease trial data By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Mineralys Therapeutics' Phase 2 Explore-CKD Study Of Lorundrostat Meets Primary Goal - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Mineralys Phase 2 Trial of Hypertension, Kidney Disease Drug Meets Primary Endpoint; Shares Up Pre-Bell - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Mineralys Therapeutics Reports Positive Phase 2 Trial Results - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

Breakthrough: Mineralys Phase 2 Drug Achieves Dual Success in Blood Pressure and Kidney Protection Trial - Stock Titan

Jun 17, 2025
pulisher
Jun 15, 2025

How the (MLYS) price action is used to our Advantage - news.stocktradersdaily.com

Jun 15, 2025
pulisher
Jun 14, 2025

Mineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street Zen - Defense World

Jun 14, 2025
pulisher
Jun 11, 2025

This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

Jefferies Initiates Coverage on Mineralys Therapeutics (MLYS) with Hold Rating | MLYS Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Jefferies Initiates Coverage on Mineralys Therapeutics With Hold Rating, $15 Price Target - MarketScreener

Jun 11, 2025
pulisher
Jun 10, 2025

Jefferies initiates Mineralys Therapeutics stock with hold rating By Investing.com - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 10, 2025

Jefferies initiates Mineralys Therapeutics stock with hold rating - Investing.com

Jun 10, 2025
pulisher
Jun 10, 2025

Cautious Outlook for Mineralys Therapeutics Amid Market Challenges and Competitive Pressures - TipRanks

Jun 10, 2025
pulisher
Jun 06, 2025

Bank of America Corp DE Has $1.33 Million Stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

BNP Paribas Financial Markets Buys Shares of 3,895 Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Mineralys Therapeutics: Merits A Small 'Speculative' Holding (NASDAQ:MLYS) - Seeking Alpha

Jun 03, 2025
pulisher
Jun 03, 2025

ProShare Advisors LLC Takes Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

Jun 03, 2025
pulisher
Jun 01, 2025

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Purchased by Deutsche Bank AG - Defense World

Jun 01, 2025
pulisher
May 28, 2025

Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat - MSN

May 28, 2025
pulisher
May 28, 2025

Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting - MSN

May 28, 2025
pulisher
May 27, 2025

Mineralys announces late-breaking presentation of data from Launch-HTN trial - Yahoo Finance

May 27, 2025
pulisher
May 26, 2025

Buy Rating for Mineralys Therapeutics: Strong Clinical Results and Growth Prospects Highlight Significant Upside Potential - TipRanks

May 26, 2025
pulisher
May 26, 2025

Mineralys reports outcomes from trial of lorundrostat for hypertension - Yahoo Finance

May 26, 2025
pulisher
May 26, 2025

MLYS: Promising Phase 3 Results for Hypertension Treatment | MLYS Stock News - GuruFocus

May 26, 2025
pulisher
May 24, 2025

Northern Trust Corp Purchases 1,688 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

May 24, 2025
pulisher
May 24, 2025

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) - The Manila Times

May 24, 2025
pulisher
May 24, 2025

Mineralys Therapeutics Reports Positive Results from Phase 3 Launch-HTN Trial of Lorundrostat for Uncontrolled Hypertension - Nasdaq

May 24, 2025
pulisher
May 24, 2025

These 3 Artificial Intelligence (AI) Stocks Look Cheap Right Now - The Globe and Mail

May 24, 2025
pulisher
May 24, 2025

Mineralys Therapeutics Inc Says Lorundrostat Shows 16.9 Mmhg Reduction At Week 6, 19.0 Mmhg At Week 12 - marketscreener.com

May 24, 2025
pulisher
May 24, 2025

Mineralys Therapeutics Announces Late-Breaking Presentation - GlobeNewswire

May 24, 2025
pulisher
May 24, 2025

Breakthrough Phase 3 Results: New Drug Cuts Blood Pressure by 19 mmHg in Largest Hypertension Trial - Stock Titan

May 24, 2025
pulisher
May 22, 2025

Mineralys Therapeutics Approves Key Proposals at Annual Meeting - TipRanks

May 22, 2025
pulisher
May 22, 2025

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going - sharewise

May 22, 2025
pulisher
May 21, 2025

Mineralys to present lorundrostat trial data at ESH 2025 - Investing.com Australia

May 21, 2025
pulisher
May 20, 2025

Mineralys to present lorundrostat trial data at ESH 2025 By Investing.com - Investing.com South Africa

May 20, 2025
pulisher
May 20, 2025

Mineralys Announces Late-Breaking Presentation Of Phase 3 Launch-HTN Trial - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection - The Manila Times

May 20, 2025

Finanzdaten der Mineralys Therapeutics Inc-Aktie (MLYS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Mineralys Therapeutics Inc-Aktie (MLYS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Rodman David Malcom
Chief Medical Officer
Jun 13 '25
Sale
14.60
11,366
165,931
101,651
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):